Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
A phase II trial with bisantrene was performed simultaneously against urothelial tumors in nude mice and in patients with metastatic transitional cell carcinoma. The starting dose was 260 mg/m2, intravenously, every 3 weeks. No responses were seen in the in vivo animal study or in 13 treated patients.